Modulation of the gut microbiome in ulcerative colitis patients

 In this study the safety and feasibility to modify the intestinal microbiome composition of a multispecies probiotic in patients with ulcerative colitis (UC) will be evaluated. The relation between the gut microbiota and UC has been an important research topic for years. Though there are many correlative findings pointing towards the impact of the fecal microbiome in UC pathogenesis, the mechanistic proof of a causative role for the microbiome in UC pathogenesis is still lacking.

It is well documented that UC patients often exhibit an aberrant (dysbiotic) intestinal microbiome after immunosuppressive therapies. The probiotic bacteria are supposed to restore the intestinal microbiome in the post-inflamed gut of the patients.

The current clinical trial will lay the premises for future follow-up trials investigating the clinical efficacy of the bacteria mix in patients with UC and may lay the groundwork to uncover the potential impact of specific multispecies-probiotics.